Adrenomed AG

📍 Hennigsdorf, Germany🗓 Founded 2009👥 18 employees💰 Last funded Jan 2025
Pharmaceutical Manufacturing🌐 adrenomed.com
Website LinkedIn
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
3
Total investors
0
Early stage
0
Mid stage
1
Late stage
2009
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Germany
1
Investor activity2018–2025 · investors recorded per year
201812024120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Adrenomed AG?
Adrenomed AG has 3 investors on record on gritt.io and 1 late-stage investors.
When did Adrenomed AG last raise funding?
The most recent investment in Adrenomed AG recorded on gritt.io was in January 2025.
When was Adrenomed AG founded?
Adrenomed AG was founded in 2009.
What industry is Adrenomed AG in?
Adrenomed AG operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Adrenomed AG based?
Adrenomed AG is headquartered in Hennigsdorf, Germany.